AJP - Endocrinology and Metabolism, Vol 268, Issue 4 E645-E651, Copyright © 1995 by American Physiological Society

ARTICLES

Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion

X. Jia, J. C. Brown, P. Ma, R. A. Pederson and C. H. McIntosh
Department of Physiology, University of British Columbia, Vancouver, Canada.

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-I-(7-36) are probably the most important "incretins," but there is controversy as to their relative insulinotropic activities. The effects of natural (np) and synthetic porcine (sp) GIP, synthetic human (sh) GIP, and GLP-I-(7-36) on insulin secretion from the perfused rat pancreas were compared using gradient perfusion. Insulin secretion was increased by both spGIP and GLP-I-(7-36) at concentrations of approximately 16 pM. Maximal responses to GLP-I-(7-36) in the presence of 16.7 mM glucose were slightly greater than with npGIP or spGIP, but with 10 mM glucose spGIP and GLP-I-(7-36) exerted equivalent effects. Responses to shGIP were greatly reduced compared with spGIP. In the presence of 50 pM spGIP or GLP-I-(7-36) the glucose threshold was 4.5 +/- 0.11 mM. The data indicate that GLP-I-(7-36) and porcine GIP are equally insulinotropic and share the same glucose threshold for activity, whereas shGIP is less active. At the concentrations found postprandially, however, GIP is likely to be the more important incretin.

This article has been cited by other articles:

				K.-H. Ding, Q. Zhong, J. Xu, and C. M. Isales Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E773 - E779. [Abstract] [Full Text] [PDF]

				S. A. Hinke, R. W. Gelling, R. A. Pederson, S. Manhart, C. Nian, H.-U. Demuth, and C. H.S. McIntosh Dipeptidyl Peptidase IV-Resistant [D-Ala2]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats Diabetes, March 1, 2002; 51(3): 652 - 661. [Abstract] [Full Text] [PDF]

				J. J. Meier, K. Hucking, J. J. Holst, C. F. Deacon, W. H. Schmiegel, and M. A. Nauck Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes Diabetes, November 1, 2001; 50(11): 2497 - 2504. [Abstract] [Full Text] [PDF]

				A. Brandt, M. Katschinski, R. Arnold, K. S. Polonsky, B. Goke, and M. M. Byrne GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E242 - E247. [Abstract] [Full Text] [PDF]

				F. C. Lynn, N. Pamir, E. H.C. Ng, C. H.S. McIntosh, T. J. Kieffer, and R. A. Pederson Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats Diabetes, May 1, 2001; 50(5): 1004 - 1011. [Abstract] [Full Text]